In this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmenopausal osteoporosis.

Start Date03 Feb 2025

Sponsor / Collaborator

The General Hospital Corp.

NCT06303284

/ Not yet recruitingPhase 1/2IIT

Post-surgical Outcomes With Anabolic Agent Use in High-risk Ankle Fractures: A Pilot RCT

As the global population ages and the prevalence of poor bone health increases among older patients with ankle fractures, so does the risk of post-surgical complications. Prevention of post-surgical complications is of paramount importance to reducing morbidity, mortality, and healthcare costs.
There is growing evidence to support the use of bone-building medications, such as Teriparatide, in patients who have delayed fracture healing or non-unions; however, these medications have yet to be investigated in elderly patients with ankle fractures at high risk for delayed fracture healing and post-operative complications. This project aims to assess the safety and efficacy of short-term Teriparatide use in improving outcomes in a population most likely to suffer post-operative complications.
The proposed study is a pilot randomized controlled trial (RCT) with patients 60 years or older with an additional risk factor for delayed healing (i.e., osteoporosis, diabetes, vascular disease) who require ankle fracture surgery. Participants will be randomized to receive the study medication (Teriparatide) or placebo for three months. The primary objective of this study is to acquire vital data (i.e., recruitment rates, follow-up rates, adherence to treatment assignment) required to determine the feasibility of a full-scale multi-centre RCT. Additional aims are to evaluate repeat surgery, complications, time-to-union, and 90-day mortality. A complete a socio-economic and feasibility analysis will be completed.
This study will evaluate the novel clinical approach of augmenting surgical fixation with a medication to build bone density and strength, thereby improving bone health, preventing complications, and improving outcomes. This study will also inform planning for a larger clinical trial to reduce the morbidity, mortality, and cost associated with complications in this high-risk population.

Start Date01 Jan 2025

Sponsor / Collaborator

University of Calgary

NCT06264609

/ Enrolling by invitationPhase 4IIT

Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover - Follow Up Study

Osteoporosis is a health problem of major proportions. It affects more than 40 million Americans and results in more than 2 million fractures annually among Medicare patients alone. Hospital admissions for osteoporotic fractures exceed those of heart attacks, strokes and breast cancer combined. Osteoporosis is commonly considered a disease associated with menopause. This estrogen deficiency related bone loss is characterized by high bone turnover with increased resorption without commensurate changes in bone formation. It is in contrast to age-related bone loss, which starts as early as in the fourth decade of life and continues with increasing age. Age-related bone loss is usually associated with lower bone turnover and decreased bone formation is the main abnormality.
Current therapies do not address age-related bone loss and the special needs of the age-related osteoporosis population is currently ignored. This is to a great degree due to difficulties associated with the bone biopsy necessary for unequivocal determination of bone turnover status. Thus, the current standard of care relies on starting with an antiresorber, which is of limited effectiveness in age-related osteoporosis, and in fact impedes the effectiveness of the appropriate anabolic medication. In a current ongoing study - Novel precision medicine approach to treatment of osteoporosis based on bone turnover. EIRB#70781; efforts are focused on addressing this particular problem.
Our follow-up study seeks to achieve one specific aim: to compare effectiveness of Alendronate vs Teriparatide after participants have been switched at the end of treatment at year one, to the other drug at year two for the same duration of treatment.

Start Date01 Feb 2024

Sponsor / Collaborator

University of Kentucky

100 Clinical Results associated with Teriparatide(Eli Lilly)

100 Translational Medicine associated with Teriparatide(Eli Lilly)

100 Patents (Medical) associated with Teriparatide(Eli Lilly)

118

Literatures (Medical) associated with Teriparatide(Eli Lilly)

01 Aug 2022·Disease models & mechanisms

Pharmacological intervention of the FGF–PTH axis as a potential therapeutic for craniofacial ciliopathies

Article

Author: Brugmann, Samantha A. ; Kristeková, Daniela ; Chang, Ching-Fang ; Bonatto Paese, Christian Louis

ABSTRACT:

Ciliopathies represent a disease class characterized by a broad range of phenotypes including polycystic kidneys and skeletal anomalies. Ciliopathic skeletal phenotypes are among the most common and most difficult to treat due to a poor understanding of the pathological mechanisms leading to disease. Using an avian model (talpid2) for a human ciliopathy with both kidney and skeletal anomalies (orofaciodigital syndrome 14), we identified disruptions in the FGF23–PTH axis that resulted in reduced calcium uptake in the developing mandible and subsequent micrognathia. Although pharmacological intervention with the U.S. Food and Drug Administration (FDA)-approved pan-FGFR inhibitor AZD4547 alone rescued expression of the FGF target SPRY2, it did not significantly rescue micrognathia. In contrast, treatment with a cocktail of AZD4547 and teriparatide acetate, a PTH agonist and FDA-approved treatment for osteoporosis, resulted in molecular, cellular and phenotypic rescue of ciliopathic micrognathia in talpid2 mutants. Together, these data provide novel insight into pathological molecular mechanisms associated with ciliopathic skeletal phenotypes and a potential therapeutic strategy for a pleiotropic disease class with limited to no treatment options.

01 Feb 2022·Expert opinion on biological therapyQ3 · MEDICINE

A randomized pharmacokinetic/pharmacodynamic study comparing the bioequivalence of potential biosimilar candidate P044 with reference medicine in healthy volunteers

Q3 · MEDICINE

Article

Author: Azhdarzadeh, Morteza ; Raykova, Ekaterina ; Ivanova, Stanislava ; Farmahini Farahani, Mohammad

BACKGROUND:

P044 is a proposed biosimilar candidate of Teriparatide for reference medicine, Forsteo®. This study was designed to evaluate the Pharmacokinetic/Pharmacodynamic (PK/PD) bioequivalence between P044 and Forsteo®.

METHODS:

In this randomized, open-label, single-dose, crossover study, 66 healthy female subjects were randomized to receive P044 and Forsteo®. The primary PK endpoints of the study were the area under the concentration versus time from zero to infinity (AUC_0-inf) and maximum plasma concentration (C_max). Secondary endpoints included area under the concentration versus time from zero to the last quantifiable concentration (AUC_0-last) and C_max for PD parameter, additional PK parameters and safety.

RESULTS:

Sixty-six subjects were enrolled in the study and baseline demographics were similar between the two treatments. The two treatments presented similar PK/PD parameters and the 90% confidence interval for primary and secondary endpoints were within the bioequivalence acceptance range (80.00-125.00%) for all parameters. None of the subjects experienced serious adverse event, and all of the reported adverse events were mild and similar between two treatments.

CONCLUSIONS:

This study demonstrated the PK/PD similarity of P044 to reference medicine, Forsteo® and safety profiles were comparable between treatments.

TRIAL REGISTRATION:

EudraCT Number: 2019-004477-82.

01 Dec 2021·Journal of medical case reports

Bilateral stress fracture of the femoral neck in association with simultaneously developing osteonecrosis of the femoral head: a case report

Article

Author: Kikuchi, Naoya ; Mishima, Hajime ; Nishino, Tomofumi ; Sugaya, Hisashi ; Watanabe, Yu ; Yamazaki, Masashi

Abstract:

Background:

Femoral neck stress fractures are rare and often recognized as overuse injuries that occur in young athletes or military personnel. A case following osteonecrosis of the femoral head is quite rare; even more uncommon is its occurrence in the bilateral hips. Magnetic resonance imaging has been established as the preferred tool for diagnosing nondisplaced femoral neck stress fracture due to overuse injury. Magnetic resonance imaging was also useful to detect the initial lesion even in this case, although the etiology was different between overuse injury and insufficiency fracture.

Case presentation:

A 41-year-old Japanese woman diagnosed with bilateral early stage idiopathic osteonecrosis of the femoral head was observed non-weight-bearing as much as possible using a stick. However, her pain and difficulty in walking progressed. Bilateral femoral neck stress fractures were subsequently detected by magnetic resonance imaging. The fracture initially appeared as a spot of bone marrow edema at the medial site of the femoral neck, and then developed into a fracture line. The patient underwent internal fixation of both hips with sliding hip screws to stabilize the stress fractures. In addition, the preparatory reaming served as core decompression of the femoral heads, as well as being treatment for osteonecrosis. Her bone mineral density and 25-hydroxy vitamin D values were low for her age. We administered eldecalcitol and teriparatide acetate. Her symptoms mostly improved, and the fracture lines and necrotic lesions on magnetic resonance imaging reduced at 5 months after the surgery.

Conclusions:

Bilateral femoral neck stress fractures are a very rare condition and are often missed. It is important to listen to the patient’s complaints and perform an appropriate examination. We encountered a case of bilateral femoral neck stress fracture that occurred in a patient with early stage osteonecrosis of the femoral head, and were able to observe progression of stress fracture since before fracture occurred. This is considered to be the first report to capture imaging changes before and after the onset.

News (Medical) associated with Teriparatide(Eli Lilly)

24 Oct 2024

·www.prnewswire.com

EpiVax and CUBRC Awarded FDA Contract Worth $2M for Development of Control Peptides for Immunogenicity Risk Assessment Assays Supporting Regulatory Filings of Generic Peptide Drugs

PROVIDENCE, R.I., Oct. 24, 2024 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") and CUBRC, Inc. ("CUBRC") announce today that they have been awarded a two-year, $2 million contract (#75F40124C00094) from the Office of Generic Drugs (OGD) of the Food and Drug Administration (FDA) to develop standardized controls for T cell assays performed to assess the immunogenicity risk of generic drugs in support of ANDA applications as outlined in the relevant FDA guidance. The new contract will establish new "standards" that may be used to enhance specificity and sensitivity across industry assay methods. Generic peptide drugs (including generic versions of well-known brands like Ozempic and Wegovy) play a vital role in improving healthcare access by providing affordable and effective treatment options at a lower cost. FDA has been working to facilitate access to needed medicines at lower costs without sacrificing standards that result in high-quality, safe, and effective medications. See, for example, information provided by the FDA here. The new FDA-funded collaboration builds on research performed by EpiVax during two previous FDA contracts that evaluated the immunogenicity risk of generic drug impurities. Under the first contract, EpiVax demonstrated the value of in silico and in vitro methods for immunogenicity risk assessment of two well-known generic peptide drugs. Under the second contract, EpiVax developed the What-if Machine (WhIM), an algorithm designed to perform iterative modifications to the amino acid sequence of a synthetic peptide drug (in silico), generating a comprehensive list of impurities for that sequence, and prospectively identifying high and low risk impurities to allow for the de-risking of drug products. This information helps to 'frame' the risk for each generic drug and may assist drug developers and FDA reviewers to differentiate impurities that are potentially riskier from those that are lower risk. For the latest research program, EpiVax will identify and qualify standard peptide-sized positive and negative controls to support generic peptide drug ANDA applications for common generic drug peptides such as teriparatide, exenatide, liraglutide and tirzepatide. EpiVax's Peptide Abbreviated New Drug Application (PANDA ®) approach uses the same orthogonal methods utilized to identify and assess potentially immunogenic impurities for the FDA. The approach is described in a review titled "Immunogenicity Risk Assessment of Synthetic Peptide Drugs and Their Impurities." The details of one of the FDA-contracted programs were expanded upon in, "Assessing the Immunogenicity Risk of Salmon Calcitonin Peptide Impurities Using In Silico and In Vitro Methods." EpiVax looks forward to executing this latest FDA-funded research in collaboration with CUBRC and continuing to improve access to safe and effective generic peptide drug products by leading in the development of new industry standards for generic peptide drug immunogenicity assessment. About EpiVax EpiVax is a leader in the industry of immunogenicity assessment and sequence optimization for peptide therapeutics, biologic therapeutics, and vaccines. EpiVax partners with a global roster of companies, agencies, and academics to accelerate immunogenicity risk assessment, immune modulation and rapid vaccine design. Visit for more information. About CUBRC CUBRC is an independent not-for-profit scientific corporation that executes Research, Development, Testing and Systems Integration programs in Medical Sciences, Chemical and Biological Defense, Data Science and Information Fusion, Command and Control, and Hypersonics. Visit for more information. FDA Funding Statement The FDA sponsors the project referenced in this press release. The content of the information does not necessarily reflect the position or the policy of the federal government, and no official endorsement should be inferred. The entire project (~$2M) will be financed with federal money. Press Contact Sarah Moniz Director, Business Development EpiVax [email protected] Logo - WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

10 Sep 2024

·www.prnewswire.com

Adcentrx Therapeutics Announces Formation of Scientific Advisory Board

Company appoints Mike Varney, Ph.D. and Kerry Blanchard, M.D., Ph.D. as founding SAB members SAN DIEGO and SHANGHAI, Sept. 10, 2024 /PRNewswire/ -- Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company focused on accelerating breakthroughs in developing protein conjugate therapeutics for cancer and other life-threatening diseases, today announces the formation of its Scientific Advisory Board (SAB) to support the advancement of its innovative Antibody-Drug Conjugate (ADC) technology platform and pipeline, including ADRX-0706, a Nectin-4 targeting ADC therapeutic currently being evaluated in a Phase 1a/b clinical trial. Continue Reading The inaugural SAB will work closely with Adcentrx's executive team to provide strategic guidance and expert insights to advance its mission of creating the best therapies to treat serious and life-threatening diseases. Formation of SAB with founding members Dr. Varney and Dr. Blanchard represents significant advancement for Adcentrx. Post this "The establishment of our SAB represents a significant advancement for Adcentrx as we progress our ADC portfolio," said Hui Li, Ph.D., President and CEO of Adcentrx. "We are privileged to welcome these exceptional scientific leaders to the Adcentrx team, and their combined expertise and guidance will be instrumental in shaping our future research and clinical development." The Founding Members of the Adcentrx SAB are: Mike Varney, Ph.D. Dr. Varney brings extensive experience in drug discovery and development, having served as Executive Vice President, Head of Genentech Research and Early Development, where he was responsible for all research activities. During his tenure at Genentech, he oversaw the discovery and development of multiple innovative therapies, including the approved cancer treatments Erivedge® and Cotellic®. Earlier in his career, Dr. Varney pioneered the use of protein-structure based drug design at Agouron Pharmaceuticals. This innovative approach led to the discovery and market approval of HIV protease inhibitor, Viracept®. After Agouron's acquisition by Warner Lambert and subsequently by Pfizer, he served as Vice President of Drug Discovery at Pfizer Global Research & Development, leading research initiatives across oncology, virology, diabetes, and ophthalmology at the La Jolla site. Dr. Varney holds a Ph.D. in Organic Synthesis from the California Institute of Technology and a B.S. in Chemistry from the University of California, Los Angeles, and was an American Cancer Society Postdoctoral Research Fellow at Columbia University. Kerry Blanchard, M.D., Ph.D. Dr. Blanchard has been a drug hunter and entrepreneur for more than four decades in the US and Asia. He is currently cofounder, Chairman, and CEO of Perpetual Medicines, a peptide therapeutics/computational AI platform company. Previously, he was the CEO of Everest Medicines, Chief Science Officer at Innovent Biologics, Senior Vice President of Lilly China Drug Development and External Innovation, and a senior executive at Eli Lilly and Company. He was a member of the board for Lilly China and Zymeworks Inc., and was the co-chairman of the Lilly Asia Ventures Investment Committee. Prior to joining Lilly in 2000, he was a tenured Professor of Medicine and Biochemistry & Molecular Biology at Louisiana State University Health Sciences Center in Shreveport, LA. Dr. Blanchard has brought four medicines to the market from his own research including Verzenio®, a CDK 4/6 inhibitor, and, his development teams in China have had more than 30 approved medicines in Asia including Trodelvy®, Trulicity®, Byetta®, Forteo®, and Tyvyt®. At Innovent and Everest, Dr. Blanchard successfully raised over $2 billion to support and expand their pipelines. His track record in accelerating clinical development and navigating regulatory landscapes will significantly enhance Adcentrx's strategic initiatives and global expansion. Dr. Blanchard received his M.D. and Ph.D. in Biochemistry from Indiana University and completed his residency and fellowships at Brigham and Women's Hospital, Dana Farber Cancer Institute, and Harvard Medical School. About Adcentrx Therapeutics Adcentrx is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. Adcentrx has pioneered the development of i-Conjugation™, an ADC technology platform addressing key components of protein conjugate design to solve challenges typically seen in ADCs. In addition to ADRX-0706, Adcentrx is developing a robust pipeline of ADCs with first-in-class potential. For more information about Adcentrx and its innovative ADC technologies, please visit . Contact Information: Investor Relations [email protected] SOURCE Adcentrx Therapeutics

Executive ChangeAcquisitionADC

19 Aug 2024

·www.echemi.com

Sirnaomics' Peptide Business Explodes! Raw Material Exports Increase by 97.51% in the First Half, Leading the Way in a $20 Billion Blue Ocean Market

Sirnaomics, a company that has been deeply involved in the peptide field for over 20 years, achieved significant growth in the export of peptide APIs in the first half of the year, with a year-on-year growth rate of 97.51%, showing its strong development momentum. Although the company experienced violent fluctuations in the capital market, its profound accumulation in the peptide field and stable performance growth have made it an important force in the industry. Sirnaomics' three core businesses - innovative drug CDMO services for peptides, peptide formulations business, and peptide API business - have collectively driven growth in performance. Of these, the API business has performed particularly well, with overseas sales growing by 97.51% year-on-year, becoming one of the main driving forces for profit growth. Peptide drugs are a type of emerging drugs that lie between small molecule chemical drugs and protein drugs, with advantages such as high activity, low toxicity, and quality control. They are suitable for solving complex diseases that are difficult to address with small molecule chemical drugs. The global peptide drug market size has already exceeded $20 billion, accounting for about 2% of the total pharmaceutical market, but it has maintained a high growth rate of around 10%. Some of the most popular peptide drugs include GLP-1 analogues, used to treat type 2 diabetes, such as liraglutide and exenatide, with sales exceeding $3 billion. Growth hormone and growth hormone-like substances are used to treat diseases caused by disorders in growth hormone secretion, with global sales of approximately $2.8 billion and $2.4 billion, respectively. LHRH agonist analogs are used to treat prostate cancer, postmenopausal breast cancer, etc., with global sales of approximately $4.8 billion. Other popular peptide drugs include teriparatide and linagliptin. In the Chinese market, sales of peptide drugs are also growing rapidly. They reached RMB 63.05 billion in 2017, mainly due to the large population base, accelerating aging, and a large number of cancer and chronic disease patients. The market demand for this will continue to expand, and there is still significant growth potential for peptide drugs. The peptide drug market is currently in a period of rapid development, and is expected to exceed $6 billion in the next 10 years. As synthetic technology advances and new indications are developed, peptide drugs will play an increasingly important role in the treatment of cancer, diabetes, and rare diseases. In recent years, as the peptide drug market has continued to expand, demand for upstream raw materials has soared. Sirnaomics has accumulated years of experience in synthesis and modification technologies, and has mastered several core technologies, solving technical bottlenecks for the production of multiple peptide raw materials. Currently, its API products have been sold to countries and regions such as Europe, the United States, and South Korea, and it has established cooperative relationships with many well-known pharmaceutical enterprises at home and abroad. In the future, Sirnaomics will continue to increase its R&D investment, enhance its peptide drug R&D capabilities and optimize production processes. It will also accelerate the implementation progress of its ongoing construction projects to seize market development opportunities. As its future capacity gradually releases, Sirnaomics is expected to drive sustained growth in its performance.

PDC

100 Deals associated with Teriparatide(Eli Lilly)

External Link

KEGG	Wiki	ATC	Drug Bank
D06078	Teriparatide(Eli Lilly)	H05AA02	DB06285

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Glucocorticoid-induced osteoporosis	Australia	Eli Lilly Australia Pty Ltd.	22 May 2003
Osteoporosis, Postmenopausal	Australia	Eli Lilly Australia Pty Ltd.	22 May 2003
Primary osteoporosis	Australia	Eli Lilly Australia Pty Ltd.	22 May 2003
Osteoporosis	United States	Eli Lilly & Co.	26 Nov 2002

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Femoral Fractures	Phase 3	Canada	Eli Lilly & Co.	01 Jul 2013
Femoral Neck Fractures	Phase 3	United States	Eli Lilly & Co.	01 Jan 2012
Femoral Neck Fractures	Phase 3	Belgium	Eli Lilly & Co.	01 Jan 2012
Femoral Neck Fractures	Phase 3	Croatia	Eli Lilly & Co.	01 Jan 2012
Femoral Neck Fractures	Phase 3	France	Eli Lilly & Co.	01 Jan 2012
Femoral Neck Fractures	Phase 3	Germany	Eli Lilly & Co.	01 Jan 2012
Femoral Neck Fractures	Phase 3	Greece	Eli Lilly & Co.	01 Jan 2012
Femoral Neck Fractures	Phase 3	Hungary	Eli Lilly & Co.	01 Jan 2012
Femoral Neck Fractures	Phase 3	India	Eli Lilly & Co.	01 Jan 2012
Femoral Neck Fractures	Phase 3	Netherlands	Eli Lilly & Co.	01 Jan 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


FDA_CDER Manual	Not Applicable	Glucocorticoid-induced osteoporosis	428	Teriparatide	kfyphyhzza(oefalcrgpp) = plwztlayrc iznnuokvps (ubkavctydi ) View more	Positive	04 Jun 2024
				prednisone or equivalent	-
FDA_CDER Manual	Not Applicable	Hypogonadal osteoporosis \| Primary osteoporosis	-	Teriparatide	oexyksurwh(geectdwmxr) = aggukhwqyk cgzwlkgclm (kmgcmchuqv ) View more	Positive	04 Jun 2024
				Placebo	oexyksurwh(geectdwmxr) = lvjdesstso cgzwlkgclm (kmgcmchuqv ) View more
FDA_CDER Manual	Not Applicable	Osteoporosis, Postmenopausal	1,637	Teriparatide	untkjqrmsa(goqfdsmapc) = mgoclsnrlw jidxlxjdqz (sqummvvcqx ) View more	Positive	04 Jun 2024
				Placebo	untkjqrmsa(goqfdsmapc) = phpzlbpnjv jidxlxjdqz (sqummvvcqx ) View more
PSAT182 (ENDO2022)	Not Applicable	Alkaptonuria \| Osteoporosis	-	Alendronate 70mg PO weekly	ftlnwqbtkz(xfzahetlhy) = ssumkrwsrn qismkscplf (evpjixquff ) View more	Positive	01 Nov 2022
EULAR2022	Not Applicable	-	25	Teriparatide + Denosumab	cwvwettsmp(kpemetwdkk) = ulbhltnouk dlxuubgbqn (wxhdsiwqbr, 3.6%) View more	-	01 Jun 2022
				Denosumab alone	cwvwettsmp(kpemetwdkk) = femiroooft dlxuubgbqn (wxhdsiwqbr, 3.6%) View more
NCT02023411 (CTgov)	Phase 2	Diabetes Mellitus \| Arthropathy, Neurogenic	20	Teriparatide (Teriparatide)	lwsrlcuofe(enfwjggpsr) = zxfqrubeuk gyoemiinve (ojlouibitn, 11.4) View more	-	16 Sep 2020
				Placebo (Placebo)	lwsrlcuofe(enfwjggpsr) = aobmnzjoxz gyoemiinve (ojlouibitn, 10.4) View more
P0903 (ERA2020)	Not Applicable	Chronic Kidney Diseases	39,128	Osteoporosis medications (bisphosphonates, raloxifene, teriparatide, or denosumab)	jfytysnuxi(ijspbecdfz) = aieixicwqq gsnfoxqwaq (frvetppqnv ) View more	Negative	06 Jun 2020
P0902 (ERA2020)	Not Applicable	iPTH \| BAP \| iP1NP ... View more	5	Teriparatide 20 µg	nxmmmozcmi(aqpkabnnhm) = 1.2±1.5% rydzkwfnsg (ofejcduwjs ) View more	Positive	06 Jun 2020
NCT01709110 (VERO, Pubmed \| Osteoporos Int)	Phase 4	Osteoporotic Fractures \| Osteoporosis, Postmenopausal \| Spinal Fractures	1,360	Teriparatide	fyaqlxpcsm(lkyagitelu): HR = 0.4 (95% CI, 0.23 - 0.68), P-Value = 0.001	Positive	30 May 2020
				Risedronate
ESPE2019	Not Applicable	Hypoparathyroidism	6	rhPTH (1-34)	hsdrpjzdux(tnlpvbwtpk) = rabnnuexpq nopuwzwstz (tljglqbfrj )	Positive	19 Sep 2019

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis